OMB review underway to unfreeze $10B in ACA payments

The Office of Management and Budget (OMC) is reviewing a rule from CMS to unlock roughly $10 billion in payments for Affordable Care Act (ACA) insurers.

The payments, which do not include taxpayer money, are made to insurers to stabilize the ACA marketplace and prevent incentives for carriers to insure only healthy people.

CMS froze the payments on July 7, citing a court decision that found they were based on flawed equations.

The “interim rule” would take effect immediately if it is approved, but no other details are available on the OMB website other than its “Ratification and Reissuance of the Methodology for the HHS-operated Permanent Risk Adjustment Program under the Patient Protection and Affordable Care Act.” 

CMS Administrator Seema Verma defended the agency’s decision to halt the payments, stating CMS’ hands were tied by the court decision.

Insurance providers and other stakeholders spoke out against the freeze of payments, with the largest health insurance lobbying group, America’s Health Insurance Plans, noting the decision comes with “serious consequences” for consumers and brings more “uncertainty” to the marketplace.

Other critics denounced the action as another attempt by the Trump administration to undermine the ACA.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.